Because our cohort did not include pure CIS cases, further studies are needed to examine whether the expression levels of p‐TFCP2L1 and CDK1 in pure CIS cases are also associated with clinical outcomes, such as recurrence‐free survival and progression to proper muscle‐invasive tumors. The gene discussed is TFCP2L1; the disease is in situ carcinoma.